Home/Pipeline/Hematologic Malignancies (CD123)

Hematologic Malignancies (CD123)

BPDCN, AML, CMML

Approved/ClinicalActive

Key Facts

Indication
BPDCN, AML, CMML
Phase
Approved/Clinical
Status
Active
Company

About Menarini

Menarini is a major, privately-held European pharmaceutical company with a diversified portfolio spanning pharmaceuticals, consumer healthcare, diagnostics, and derma-aesthetic medicine. It leverages a fully integrated model from R&D to global commercial execution, with a significant strategic focus on oncology and a strong partnering heritage. The company is actively investing in advanced science to build a pipeline for serious conditions while maintaining a core commitment to its values and corporate responsibility.

View full company profile